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ABSTRACT: Protein kinase C (PKC) isozymes play central roles in the signal transduction 
on the cell surface and could serve as promising therapeutic targets of intractable diseases like 
cancer, Alzheimer’s disease, and acquired immune deficiency syndrome (AIDS). Although 
natural PKC ligands like phorbol esters, ingenol esters, and teleocidins have the potential to 
become therapeutic leads, most of them are potent tumor promoters in mouse skin. By 
contrast, bryostatin-1 (bryo-1) isolated from marine bryozoan is a potent PKC activator with 
little tumor-promoting activity. Numerous investigations suggested bryo-1 to be a promising 
therapeutic candidate for the above intractable diseases. However, there is a supply problem 
of bryo-1 both from natural sources and by organic synthesis. Recent approaches on the 
synthesis of bryo-1 have focused on its simplification, without decreasing the ability to 
activate PKC isozymes, to develop new medicinal leads. Another approach is to use the 
skeleton of natural PKC ligands to develop bryo-1 surrogates. We have recently identified 
10-methyl-aplog-1 (26), a simplified analog of tumor-promoting aplysiatoxin (ATX), as a 
possible therapeutic lead for cancer. This review summarizes recent investigations on the 
simplification of natural PKC ligands, bryo-1 and ATX, to develop potential medicinal leads. 
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Introduction 
Natural products as secondary metabolites have been considered to be possible lead 
compounds for treatment of human diseases. However, natural products themselves cannot be 
used as drugs in general because they have adverse effects in addition to the desirable effects; 
furthermore, they cannot be obtained in sufficient amounts from natural sources and their total 
synthesis normally requires multiple steps. It is reported that over 50% of the approved drugs 
from 1981 to 2010 were synthetic small compounds and that “natural product medicines” 
such as daptomycin, artemisinin, trabectedin, and paclitaxel (taxol) were rare cases (ca. 6%).[1] 
It is obvious that nature does not make compounds for human health care. Moreover, recent 
investigations have revealed the multiligandable nature of natural products.[1b] Many natural 
products should be regarded as “a bunch of keys” that have many cellular targets. To develop 
medicinal leads from natural products, it is indispensable to identify the structural motif (a 
special key) that is responsible for desirable effects. Function-oriented synthesis of natural 
products or the synthesis of suitably truncated ligands is one of the promising approaches to 
obtain new medicinal leads.[2] 
The development of eribulin mesylate (Halaven)[3] is one of the successful examples. 
Halicondrin B[4] is a marine natural product with potent anticancer activities isolated from the 
marine sponge Halichondria okadai. After synthesizing over 200 derivatives of halicondrin B 
(conventional structure–activity studies), eribulin was found to be effective against breast 
cancer. This was an extremely hard work, and thus more rational approaches are necessary to 
uncover the essential structure of natural products that possesses the same desirable effects. If 
their main targets were identified, structural analysis of a ligand–target complex based on 
X-ray crystallography and/or NMR studies would shorten the procedure. 
This review focuses on the development of simplified analogs of two natural 
products, bryostatin-1 (bryo-1)[5] and aplysiatoxin (ATX)[6], as potential medicinal leads for 
intractable diseases. The main targets of these compounds are identified as protein kinase C 
(PKC) isozymes,[7] a key enzyme family involved in cell surface signal transduction. PKC 
isozymes are attractive targets in the treatment of cancer,[8] Alzheimer’s disease (AD),[9] 
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acquired immune deficiency syndrome (AIDS),[10] vascular complications of diabetes,[11] and 
neuropathic pain.[12] 
 
Protein kinase C and C1 domain receptors 
Protein kinase C (PKC) is a family of serine/threonine kinases involved in cellular 
signal transduction via a second messenger, 1,2-diacyl-sn-glycerol(DG).[7] Tumor-promoting 
phorbol esters, teleocidins, and aplysiatoxins activate PKC isozymes by binding to the C1 
domains in the regulatory region.[7a,13] PKC isozymes activated by tumor promoters and DG 
are conventional PKCs (α, βI, βII, and γ) and novel PKCs (δ, ε, η, and θ) (Fig. 1a).[7b] The 
former are also regulated by calcium ions, but the latter are insensitive to calcium despite the 
fact that they have a C2-like domain at the N-terminus. All of these PKC isozymes have two 
C1 domains (C1A, C1B),[14] to which natural PKC ligands and DG bind in the presence of 
phosphatidylserine. They are inactive under physiological conditions because the C-terminal 
kinase domain is occupied by a pseudosubstrate sequence of the N-terminus. However, the 
binding of tumor promoters or DG to the C1 domains of the PKC isozymes induces their 
translocation from the cytoplasm to the plasma membrane, where they become activated (Fig. 
1b). Nuclear translocation also occurs when the ligands are hydrophilic, as exemplified in 
phorbol esters with short acyl chains and bryo-1.[15] 
Since each C1 domain consists of a cysteine-rich sequence of 50 amino acid 
residues,[14] we synthesized all C1 peptides by solid-phase peptide synthesis to determine the 
Kd values for [3H] phorbol 12,13-dibutyrate (PDBu).[16] Both C1 peptides of conventional 
PKCs, except for PKCα-C1B, showed potent binding to PDBu comparable to that for the 
whole PKCs. On the other hand, only the C1B peptides of novel PKCs bound strongly to 
PDBu. It is noteworthy that PDBu bound to at least one of the C1 domains of all conventional 
and novel PKCs with Kd values of 0.5-1.5 nM (Table 1).[16d] The Ki values for the C1 peptides 
of indolactam-V,[17] a biosynthetic precursor of tumor-promoting teleocidins,[17d,e] obtained by 
the inhibition of [3H]PDBu binding were almost equal to those of the corresponding whole 
PKC isozymes obtained by the well-established procedure of Blumberg’s group[18] (Table 
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1).[19] Thus, the C1 peptide library gives a unique opportunity for finding compounds with 
PKC isozyme and/or C1-domain selectivity. 
However, PKC isozymes are not sole receptors for tumor-promoting phorbol esters 
and DG (Fig. 2). Recent investigations revealed that protein kinase D (PKD), diacylglycerol 
kinase (DGK) β and γ, chimaerins (α1, α2, β1, and β2), Ras guanyl nucleotide-releasing 
protein (RasGRP) 1, 3, and 4, and Unc13s (Munc-13-1, -2, and -3), bound potently to PDBu 
and DG.[8b,20] These proteins have at least one C1 homology domain present in PKC isozymes. 
By contrast, there are several proteins with C1 homology domains that do not bind to PDBu 
and DG. They include atypical PKCs (ζ and ι), DGKs other than DGKβ and γ, RasGRP2, 
c-Raf (a kinase suppressor of Ras), and Vav1 (a guanine nucleotide exchange factor).[20,21] 
Since PKCs and some of the other C1-domain-containing proteins are involved in 
diverse biological events like proliferation, differentiation, apoptosis, angiogenesis, and so on, 
they are attractive targets for cancer and other diseases such as AD and AIDS. Natural PKC 
ligands like phorbol esters might serve as their therapeutic leads. In fact, 
12-O-tetradecanoylphorbol 13-acetate (TPA) and ingenol 3-angelate were subjected to 
clinical trials for some cancers.[22] However, they might elicit tumor-promoting activity and 
severe inflammation as off-target activities. Since these compounds exhibit pleiotropic effects 
like cell differentiation, cell adhesion, and virus induction other than tumor-promoting and 
inflammatory activities, they should be regarded as “a bunch of keys” or “a master key”. 
Suitable derivatization of phorbol esters, indolactam compounds, or DG might separate 
desirable activities from off-target activities. Wender’s highly potent prostratin analogs,[23] 
Kozikowski’s benzolactam compounds,[24] and Marquez’s DAG-lactones[25] could be 
successful examples (Fig. 3). Indolactam-V, the basic ring-structure of teleocidins, is a weak 
tumor promoter,[26] but showed anti-proliferative effects against several cancer cell lines 
(unpublished results). However, such attempts to separate desirable activity from off-target 
activity like tumor-promoting activity seems to be quite difficult with phorbol esters and 
teleocidins since there is a good correlation between their tumor-promoting activity and 
ability to activate PKC isozymes.[27] 
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Bryostatin-1, a unique PKC activator with anti-proliferative activity 
Bryostatin-1 (bryo-1) is a mysterious PKC activator with little tumor-promoting 
activity and antagonizes the effects of TPA in several cell lines.[28] Major differences between 
bryo-1 and tumor promoters like TPA and teleocidin B-4 are the 
hydrophobicity/hydrophilicity of the molecules. TPA and teleocidin B-4 are highly 
hydrophobic molecules (calculated log P > 6.0) while bryo-1 is hydrophilic (log P = 2.9).[29] 
The hydrophobicity of phorbol or teleocidin derivatives correlated well with their binding 
potency to PKC isozymes as well as their tumor-promoting activity.[15a,27] However, the 
hydrophilic compound bryo-1 binds strongly to PKC isozymes with a potency similar to 
phorbol and ingenol esters.[28b,30] Although the reason why bryo-1 behaves like this remains 
unknown, its larger molecular size might be related to this behavior. 
Bryo-1 has attracted much attention as a therapeutic agent for cancer treatment due 
to its unique character as a potent PKC activator without tumor-promoting activity and its 
abilities to induce apoptosis, to reverse multidrug resistance, and to modulate the immune 
system. Hitherto, the anticancer activity of bryo-1 for solid or blood cancers including 
epithelial ovarian cancer, advanced pancreatic carcinoma, myeloid, advanced esophageal 
cancer, and so on, has been investigated in at least 43 phase I and II clinical trials.[8,31] Since 
most of these trials with the independent application of bryo-1 were disappointing,[31] its 
combination with some anticancer drugs like paclitaxel,[32] cisplatin,[33] or vincristine[34] has 
also been carried out. Among them, bryo-1 in combination with vincristine was found to be 
effective in selected patients with aggressive non-Hodgkin’s lymphoma (NHL).[34] Moreover, 
the results of bryo-1 and fludarabine in the treatment of progressive chronic lymphocytic 
leukemia (CLL) or refractory indolent NHL were encouraging.[35] A major adverse effect of 
bryo-1 is myalgia, the mechanism of which is unclear.[36] While bryo-1 had promising effects 
for the treatment strategy against AD and HIV infection, clinical trials for these diseases have 
not yet been conducted. 
Overall, bryo-1 has a broad therapeutic potential. However, it is a very rare natural 
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product. Only 18 g of bryo-1 was obtained from 14 tons of marine bryozoan.[37] Since it has 
been used in numerous clinical trials, it is almost out of stock. It is quite difficult to purchase 
bryo-1 even for mechanistic studies as 10 µg cost $250 (Sigma, USA). Bryo-1 congeners (e.g., 
bryo-7 and bryo-10)[38] could be used instead of bryo-1 (Fig. 4). In fact, a recent investigation 
on bryo-7 revealed that it could become a surrogate of bryo-1.[39] Although over 20 congeners 
of bryo-1 have been isolated, their abundance is quite low.[38] In our recent attempt to isolate 
bryostatin congeners, we only obtained 3 mg of bryo-10 from 6 kg of Japanese bryozoan as a 
major product.[40] 
Synthetic studies on bryo-1 and its natural congeners have been extensively carried 
out. Initial studies on the total synthesis of bryo-7, bryo-2, and bryo-3 required about 75-90 
steps in total;[41] however, in recent studies on bryo-7, bryo-16, bryo-1, and bryo-9, the 
number of steps required was shortened to about 35-70.[42] However, amounts sufficient for 
clinical studies cannot be supplied at present. Genetic engineering is not practical since bryo-1 
is a molecule too large to be synthesized using E. coli.[43] 
 
Development of simplified analogs of bryostatin-1 with potent 
anti-proliferative activity against several cancer cell lines 
To overcome the supply problem, the development of simplified analogs of bryostatin-1 
(bryo-1) with equally potent anti-proliferative activity could be an effective strategy. Wender 
noticed this in the early 1980’s and designed a simplified PKC analog based on the 
pharmacophoric model of phorbol esters.[44] In 1998, the first simplified analog of bryo-1 (1, 
bryolog) was synthesized by Wender and co-workers.[45] They thought that the bottom half of 
bryo-1 containing the C-ring is strictly recognized by PKC isozymes,[44b] but that its A- and 
B-rings play only a role to fix the molecule in a suitable conformation. The B-ring was thus 
replaced with a dioxane for acetal-driven macrocyclization. The designed analog 1 showed 
potent binding to a PKC isozyme mixture with a Ki value of 3.4 nM, which is comparable to 
that of bryo-1 (1.35 nM). 
Since then, Wender’s group has synthesized over 100 analogs of bryo-1 to 
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investigate the structure–activity relationship in PKC binding. Deletion of the asymmetric 
methyl group at position 26 significantly enhanced the PKC binding with a Ki value of 0.25 
nM (2, picolog).[46] More importantly, such simplification enhanced the binding selectivity to 
novel PKC isozymes.[47] Especially, the C7-OH and C8 dimethyl analog (3) showed 
PKCδ-selective membrane translocation in CHO-K1 cells over PKCβI, whereas bryo-1 
induced the membrane translocation of both isozymes.[47b] Although the A-ring itself proved 
to be unnecessary for PKC binding, substitution of the six-membered B-ring with a 
five-membered ring changed the compound into one selective for novel PKC isozymes 
similar as observed for 3.[47c] Modification of the B-ring has been accomplished through a 
Prins-driven macrocyclization strategy to yield 4.[48] The molecular basis for the change of the 
PKC isozyme selectivity remains elusive. 
The anti-proliferative activities of these analogs against several cancer cell lines 
were examined at the National Cancer Institute. The corresponding data for 1 and 2 are 
summarized in Table 2 along with those of bryo-1 as a control.[46] The data clearly suggest 
that these analogs are superior to bryo-1 in the anti-proliferative activities against several 
cancer cell lines. Accordingly, they might become bryo-1 surrogates in future clinical trials. 
However, their off-target activity such as tumor-promoting activity and inflammation has not 
yet been reported.   
Recently, Keck and colleagues have synthesized several analogs of bryo-1 
simplified at the A- and B-rings (5 and 6).[49] They examined the effects of A- and B-ring 
modifications on the proliferation and attachment of U-937 human leukemia cells. 
Unexpectedly, the behavior of 5 in U-937 cells was similar to that of TPA. By contrast, 6 
which lacks only the carbomethoxy group at the B-ring of bryo-1 displayed the same 
properties as bryo-1 in the assay using U-937 cells; unlike TPA, both 6 and bryo-1 did not 
inhibit proliferation of U-937 cells. These results indicate that the A-ring of bryo-1 plays a 
significant role in its unique biological activities. So far, however, the in vivo 
tumor-promoting activity of bryo-1 has only been reported in one study.[28a] In the reported 
work, in which SENCAR mice were used, the amount of bryo-1 for topical application was 
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equal to that of TPA (1.7 nmol/mouse). Further experiments with a high dose of bryo-1 and 
its analogs (at least 5- fold excess of TPA) seem to be necessary. 
Although both TPA and bryo-1 are potent PKC activators, the former is a potent 
tumor promoter while the latter is not.[28a] Moreover, bryo-1 antagonizes many cellular 
responses induced by TPA.[28c] Bryo-1 blocked the TPA-induced differentiation of a human 
colon cancer cell line and the human promyelocytic leukemia HL-60 cell line.[50] The 
mechanistic difference between TPA and bryo-1 in U-937 human myeloid leukemia cells has 
recently been investigated.[51] The enhanced m-RNAs (top 20) were almost similar to each 
other. However, the response to bryo-1 was transient while that to TPA was continuous. 
Another difference is that TPA, but not bryo-1, induces a down-regulation of PKCδ,[52] which 
plays a tumor suppressor role. In primary mouse keratinocytes, bryo-1 at low concentrations 
(<1 nM) down-regulated PKCδ to a similar extent as TPA; however, at high concentrations 
(>100 nM) bryo-1 did not down-regulate PKCδ but protected it from TPA.[52a] This might be 
ascribable to the cellular membrane translocation of PKCδ by TPA and to the nuclear 
membrane translocation by bryo-1.[15] However, TPA as well as bryo-1 did not down-regulate 
PKCδ in K562 cells (a human immortalised myelogenous leukemia line), whereas bryo-1, but 
not TPA, down-regulated PKCε and RasGRP3.[49d] The pattern of cellular response to TPA 
and bryo-1 might therefore vary depending on the conditions and/or cell lines. Since bryo-1 is 
regarded as a bunch of keys, its simplified analogs would be powerful tools to reveal some 
stages of the mechanism of bryo-1. For example, Wender’s analogs[48] with selectivity against 
novel PKC isozymes could be useful. 
 
Development and biological activities of the simplified analogs of 
debromoaplysiatoxin 
Analog design: Even the synthesis of Wender’s simplified analogs of bryo-1 requires at least 
about 30 steps, of which some are technically difficult.[46,48] The development of synthetically 
more accessible compounds with bryo-1 like activities is thus necessary. After scrutiny of 
natural PKC ligands, we decided to use the skeleton of aplysiatoxin (ATX),[6] which is 
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isolated from the digestive gland of the sea hare Stylocheilus longicauda, to develop a bryo-1 
surrogate. The main reason to adopt the ATX structure is that it is regarded as a 
conformationally fixed analog of endogenous DG, though the atom sequence of one ester 
carbonyl moiety is reversed (Fig. 5). In addition, ATX and bryo-1 share the common 
structural feature of a macrolactone. The most interesting structural character of ATX in its 
biological activities is the role of the bromine atom in the side chain. The tumor-promoting 
activity of debromoaplysiatoxin (DAT) is significantly weaker than that of ATX, while the 
binding potency to PKC isozymes is quite similar.[53] This characteristic was not observed in 
phorbol esters and teleocidins, where hydrophobicity plays a critical role in their 
tumor-promoting activity and binding potency to PKC isozymes. 
Unlike bryo-1, ATX is a potent tumor promoter.[53b] The simplification should thus 
be done so as to reduce the tumor-promoting activity without decreasing the binding potency 
to PKC isozymes, if possible, to PKCδ, which plays a tumor suppressor role,[54] because the 
activation levels of PKCα, β, and ε are elevated in tumor tissues.[8b,8c] First, we designed three 
simplified analogs (7-9).[55] Four chiral methyl groups and a methoxy group as well as a 
bromine atom were removed to decrease the hydrophobicity and synthetic difficulty. 
Moreover, the labile hydroxyl group at position 3 was replaced with a hydrogen atom to 
increase its stability. Compound 7, named aplog-1, has geminal methyl groups at the 
spiroketal moiety and a phenolic hydroxyl group at the benzene ring. Compound 8 lacks the 
phenolic hydroxyl group, and 9 lacks both. The calculated log P values (partition coefficients 
between n-octanol and water) of TPA, teleocidin B-4, and ATX exceed 5.0, while those of 
these analogs are less than 3.0, which are values comparable to the measured log P value of 
bryo-1 (2.9).[29]  
We thought that the dimethyl groups of the spiroketal at position 6 of ATX could be 
more important compared to other methyl groups at positions 4, 10, 12, or 30 to retain the 
binding ability to PKC isozymes based on the pharmacophoric model of PKC activators.[44,56] 
Polar groups like oxygen functionality at positions 12 and 13 of phorbol esters remarkably 
reduced the PKC binding potency; phorbol or phorbol 13-acetate could only weakly bind to 
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PKC isozymes. The positions 12 and 13 of phorbol esters corresponds roughly to the 
positions 6 and 11 of ATX on the pharmacophore model.[44,56]  Since one of the oxygen atom 
at the spiroketal moiety directs outer side of the macrolactone ring, it would be indispensable 
to protect the oxygen atom by the hydrophobic dimethyl groups at position 6 to form the 
complex with each PKC isozyme and phosphatidylserine.  On the basis of this consideration, 
7 was designed as a first simplified analog of ATX with substantial affinity to PKC isozymes 
without tumor-promoting activity. 
 
Synthesis of aplog-1 and its congeners: The total synthesis of ATX first reported by Kishi 
and co-workers comprised over 53 steps.[57] Subsequently, the synthesis of its related 
compounds was carried out by the groups of Katsuki[58] and Yamamura.[59] The synthetic 
difficulty is the instability of the hydroxyl group at position 3 and the 
hydrogenolysis-sensitive methoxy group at the side chain. Because of this difficulty, the 
synthesis by Ireland et al. did not accomplish the total synthesis of ATX.[60] Since aplog-1 (7) 
is a highly simplified analog of ATX, the synthetic route was quite different from those of the 
four groups mentioned above. 
As shown in Fig. 6, m-hydroxycinnamic acid was converted into the aldehyde 11 in 
8 steps. Asymmetric Keck’s allylation[61] of 11 provided 12, which was followed by Smith’s 
iodocarbonate cyclization reaction,[62] methanolysis, and protection, to yield the epoxide 13. 
Coupling of the epoxide moiety in 13 with the dithiane unit 14 following the protocol of Ide 
and Nakata,[63] and subsequent conversions provided the aldehyde 15. Keck’s allylation of 15 
produced then the homoallylic alcohol 16, which was hydrolyzed to form the desired 
spiroketal 17 in 49% yield. The undesired spiroketal 18 was partially converted into 17 by 
treatment with pyridinium p-toluenesulfonate (PPTS). Although 17 seems to be more stable 
than 18 due to intramolecular hydrogen bonding, 18 might be stabilized by a double anomeric 
effect. Condensation of the spiroketal 17 with the carboxylic acid 19 using Yamaguchi’s 
method[64] yielded 20, the p-methoxybenzyl (MPM) group of which was substituted with the 
triethylsilyl (TES) group. Oxidative cleavage of the double bond, followed by Yamaguchi’s 
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lactonization and deprotection, gave Aplog-1 (7).[55a] The total yield of 7 over 27 steps was 
1.5%. Aplog-2 (9), which does not contain the dimethyl group at the spiroketal moiety and the 
hydroxyl group in the benzene ring, was similarly synthesized.[55a] DM-aplog-2 (8) was 
obtained from 7 by catalytic hydrogenation.[55b] 
The log P value of 7 was estimated experimentally by high-performance liquid 
chromatography (HPLC), as recommended by OECD.[65] The retention time of 7 on a 
reverse-phase column could be correlated to the log P values using appropriate reference 
compounds with known log P values. The log P value of 7 (3.3)[66] was almost equal to that of 
bryo-1 (2.9) reported by Bignami et al.[29] 
 
Biological activities of aplog-1 (7) and its congeners: The binding of aplog-1 (7) and its 
derivatives (8 and 9) to the C1B domain of PKCδ, whose activation might be related to the 
unique biological activities of bryo-1,[15b] are shown in Table 3. Compound 7 showed potent 
binding to the C1B domain with a Ki value of 7.4 nM. The binding affinity of aplog-2 (9) 
without the dimethyl and phenolic hydroxyl groups was 20 times weaker than that of 7. By 
contrast, DM-aplog-2 (8) showed a binding affinity similar to that of 7, thus indicating that 
the dimethyl group at the spiroketal moiety plays a significant role in the PKC binding.[55a] 
The most critical point in developing a bryo-1 surrogate from ATX is to make 
structural modifications that result in a decrease in the tumor-promoting activity. The skin of 
the back of ICR mice was first treated with a single dose of 100 µg of 
7,12-dimethylbenz[a]anthracene (DMBA), a strong carcinogen, and one week later with 8.5 
nmol of 7. Whereas an amount as low as 1.7 nmol (one fifth) of TPA or DAT resulted in 
significant tumor-promoting effects as reported previously,[53b] 7 did not show any 
tumor-promoting effects and inflammation at this higher dosage (unpublished results). 
To evaluate the anti-proliferative activities of 7-9, a panel of 39 human cancer cell 
lines established by Yamori and co-workers was employed.[67] The average of the log GI50 
values (where GI50 denotes the concentration required for inhibiting cell growth by 50% 
compared to an untreated control) for all 39 human cancer cell lines were expressed as a 
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MG-MID (mean-graph midpoint). The cell lines with log GI50 values less than –5.00 are listed 
in Table 4. To our delight, 7 exhibited a significant activity comparable to that of bryo-1 
against several cancer cell lines. Compound 9 without the dimethyl and hydroxyl groups 
showed an activity that was one order of magnitude lower. The activities of 7 and 8 were 
similar. The affinity for PKCδ and anti-proliferative activity correlated well. After publication 
of these data, 7 was featured in “this week in therapeutics” of Science–Business eXchange.[68] 
As mentioned above, PKCδ is considered to be one of the major targets of 
bryo-1.[15b] We found that 7 exhibited an activation profile for PKCδ similar to that of 
bryo-1.[55a] Upon the treatment of PKCδ with 7 or bryo-1, PKCδ translocated from the cytosol 
to the nuclear membrane and perinuclear region in CHO-K1 (Chinese hamster ovary) cells, 
while TPA induced mainly translocation to the plasma membrane. To examine the correlation 
between PKCδ binding and anti-proliferative activity, we prepared three derivatives of 
aplog-1 (21-23) that differ in the ability to bind PKCδ.[69] These are 27-(R)-methyl-aplog-1 
(21), which has an absolute configuration at position 27 that is the same as that of DAT at 
position 30, the 27-epimer of 21 (22), and 27-O-methyl-aplog-1 (23) (Fig. 5). As expected 
from previous structure-activity studies on DAT,[56b] 21 bound to and activated PKCδ with a 
potency similar to 7, while 22 and 23 were completely inactive. 
The anti-proliferative activities of 21-23 were evaluated using the aforementioned 
panel of 39 human cancer cell lines. The cell lines with log GI50 values of aplog-1 (7) less 
than –5.50 are listed in the upper half of Table 5.[69] Compound 21 as well as 7 showed 
significant anti-proliferative activities. By contrast, 22 and 23 exhibited weak activities in 
these cell lines. These data suggest that aplog-1 and its derivatives (8, 9, and 21) might inhibit 
the growth of cells of these cancer cell lines through a PKCδ-dependent mechanism. As a 
reference, several aplog-insensitive cell lines (log GI50< –5.00) are also listed in the lower half 
of Table 5. They might constitute cell lines with a lower degree of PKCδ expression or a 
higher degree of expression of other PKC isozymes. The involvement of PKCδ in the 
anti-proliferative activities of the aplog-sensitive cancer cell lines might be demonstrated by 
knockout of each PKC isozyme using siRNA. However, targets other than PKC isozymes 
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might also exist that are responsible for the activities of aplogs, as 22 and 23 had a weak bjt 
substantial anti-proliferative activity. 
 
Structure-activity studies on the phenol side chain of aplog-1 (7): The next step is to 
optimize the anti-proliferative activity of 7 without increasing off-target activities such as 
tumor-promoting activity and inflammation. The simplest way for this purpose is to modify 
the phenolic side chain of 7 that is deduced to be involved in non-specific hydrophobic 
interactions with phospholipids when bound to PKC isozymes.[56] As shown in Fig. 7,[66] the 
change in the anti-proliferative activity (–MG-MID) was dominated by the change in the log 
P values of the aplog-1 derivatives, which were determined by the HPLC as mentioned above. 
The optimal range of log P proved to be 4.0-4.5, which corresponds to that of the 
mono-halogenated derivative of 7. However, the increase in MG-MID of 21-bromo-aplog-1 
(–5.20) and 21-iodo-aplog-1 (–5.19) in comparison with 7 (–4.98) was only about 0.2. This 
indicates that a suitable modification at the macrolactone ring of 7 is indispensable for 
developing highly potent analogs. It is also noteworthy that 21-bromo-aplog-1 did not show 
any tumor-promoting activity in a two-stage carcinogenesis experiment using ICR mice even 
when applied at a five-fold excess compared with DAT and TPA.[66] 
DAT has an asymmetric methoxy group at the side chain. To investigate the role of 
this functional group in the biological activities, demethoxy-DAT (24) was derived from DAT 
by catalytic hydrogenation.[70] The two-stage carcinogenesis test in mouse skin suggested that 
24 is a significantly weaker tumor promoter than DAT. By contrast, 24 showed a stronger 
anti-proliferative activity compared with DAT against several aplog-sensitive cancer cell lines, 
as shown in Tables 4 and 6. These data suggest that the methoxy group at the side chain could 
increase the tumor-promoting activity. 
 
Structure-activity studies on the spiroketal moiety of aplog-1 (7): Since the 
hydrophobicity around the spiroketal moiety of 7 plays a critical role in PKCδ binding and 
anti-proliferative activities as exemplified in aplog-2 (9), methyl groups were installed 
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systematically into position 4, 10, or 12 of 7. These derivatives were synthesized by the 
method employed in the synthesis of 7 with suitable modifications.[71] Interestingly, 
10-methyl-aplog-1 (26) bound to the C1B domain of PKCδ with a Ki value of 0.46 nM, 7-20 
times stronger than 4-methyl-aplog-1 (25, 3.3 nM), 12,12-dimethyl-aplog-1 (27, 9.1 nM), and 
aplog-1 (7, 7.1 nM). The anti-proliferative activities of these analogs against “aplog-sensitive” 
cell lines are shown in Table 6. Compound 26 exhibited 5-20 times stronger inhibitory effects 
on the growth of aplog-sensitive cell lines than 7, 25, and 27. The MG-MID of 26 (–5.24) was 
nearly equal to that of the tumor-promoting DAT (–5.22). 
Since the hydrophobicity is a critical factor for increasing the tumor-promoting 
activity, the tumor-promoting activity of 26 and 27 was examined in vivo by the method 
mentioned above. The skin of the back of ICR mice was treated with a single dose of 100 µg 
of DMBA and, one week later, with 8.5 nmol (5-fold excess of TPA and DAT) of 26 or 27. 
These aplogs did not show any tumor-promoting effects under these conditions.[71b,72] In a 
control experiment, 1.7 nmol of TPA led to a significant tumor-promoting effect. Moreover, 
27 was shown to be a suppressor of TPA as reported for bryo-1 (Fig. 8).[72] 
The anti-proliferative activity of 26 against several aplog-sensitive cell lines was 
even higher than that of DAT, as shown in Table 4, whereas 26 showed little 
tumor-promoting activity unlike DAT. These results suggest that DAT should be regarded as 
“a master key” for pleiotropic effects like tumor promotion in addition to anti-proliferative 
activity, while 26 should be regarded as “a special key” for anti-proliferative activity. 
Compound 26 could therefore become a possible medicinal lead for cancer treatment. 
 
The mechanism underlying the unique biological activities of aplogs: The activation of 
PKC isozymes could be related to the anti-proliferative and tumor-promoting activity of 
aplogs. Recent investigations revealed that each PKC isozyme mediates unique cellular 
functions and phosphorylates unique protein substrates.[7] However, their roles in tumor 
promotion, inflammation, or cell proliferation are complicated and controversial. For 
example, PKCα is found to be important for inflammation and proliferation, but appears to 
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suppress tumor promotion, and the DMBA/TPA protocol did not induce squamous cell 
carcinoma in PKCα knockout mice.[73] Another study contradictorily reported that a low dose 
of TPA promoted the papilloma in PKCα-overexpressing mice but not in wild-type mice.[73d] 
PKCε transgenic mice exhibited enhanced carcinoma formation but reduced tumor 
promotion.[74] By contrast, PKCδ transgenic mice were resistant to skin tumor promotion,[75] 
and PKCη knockout mice were more susceptible to tumor promotion.[76] Taken together, 
although PKC isozymes (α, δ, ε, and η) might play a tumor suppressor role, PKCα and ε 
appear to enhance tumor progression, and in some cases PKCα could enhance tumor 
promotion. 
Using our synthetic PKC C1 peptide receptors,[16] we found that aplog-1 (7) and 
10-Me-aplog-1 (26) differed from the tumor promoters DAT, indolactam-V, and PDBu in 
their affinity for PKC isozymes (Fig. 9).[71b,72] The C1A peptides were used as conventional 
PKC surrogates, whereas the C1B peptides were used as novel PKC surrogates because these 
peptides are main binding sites of PDBu.[16d] Tumor promoters like DAT, indolactam-V, and 
PDBu bound significantly to both conventional and novel PKC isozymes. By contrast, the 
anti-proliferative aplogs bound selectively to novel PKC isozymes, that is, PKCδ, η, and θ. It 
is interesting that Wender’s simplified analogs of bryo-1 also showed novel PKC isozyme 
selectivity.[48] Bryo-1 itself was selective for novel PKCs in our assay system using PKC C1 
peptides,[30] whereas the data of Kazanietz et al. using whole PKC isozymes are slightly 
different from our results.[28b] However, the relative binding affinity against conventional 
PKCα and β was lower for bryo-1 compared with PDBu. These results suggest that the 
unique biological activities of aplogs might be ascribable in part to the ability to bind PKCδ 
and η, although weak binding to conventional PKC isozymes might also be important. 
A number of studies revealed the involvement of PKCδ in apoptosis signaling in a 
variety of cell types.[77] PKCδ plays important roles in both receptor-mediated and 
DNA-damage-induced cell death. For example, in U-937 (a human leukemia cell) and 
MCF-7 (a breast cancer cell), TPA induced translocation of PKCδ to mitochondria and 
subsequent release of cytochrome c. Several lines of evidence support the notion that the 
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cleavage of PKCδ by caspase and nuclear translocation of the fragment is required for the 
apoptosis event. In LNCaP (an androgen-sensitive human prostate adenocarcinoma cell), 
PKCδ mediated TPA-induced apoptosis without its cleavage by caspase-3. PKCδ is also 
involved in cell cycle arrest in G1/S and G2/M phases. Therefore, activation of PKCδ by 
aplogs might contribute to its anti-proliferative effect in certain cell types (Fig. 10). However, 
PKCδ provides survival signaling in some cases.[77c,78] Further investigations on the 
regulation mechanism of PKCδ and other isozymes are required for the development of safer 
PKC ligands for anti-cancer therapy.  
  
Summary and Outlook 
Natural PKC ligands like phorbol esters have the potential to become therapeutic 
leads for intractable diseases, such as cancer, Alzheimer’s disease, and AIDS, but most of 
them are potent tumor promoters. Bryostatin-1 (bryo-1) isolated from marine bryozoan is a 
fascinating PKC activator without tumor-promoting activity. Although bryo-1 is a promising 
therapeutic candidate for these intractable diseases, amounts sufficient for clinical trials could 
not be supplied both by isolation and organic synthesis. Hence, the development of simplified 
analogs of bryo-1 could be a highly effective strategy.[45-49] 
As an alternative way to address the supply problem, we developed simple, easily 
produced aplysiatoxin analogs as possible anti-cancer leads.[55,71,72] Although 
debromoaplysiatoxin (DAT) is a tumor promoter, 10-methyl-aplog-1 (26) did not show any 
tumor promotion in vivo even when applied in 5-fold excess compared with DAT.[71b] 
Interestingly, the anti-proliferative effects on 39 human cancer cell lines (MG-MID) were 
quite similar to each other, and the anti-proliferative activity of 26 against several cancer cell 
lines was even higher than that of DAT. These data indicate that the removal of three methyl 
and one methoxy groups along with a hemiacetal hydroxyl group reduced only the 
tumor-promoting activity. Such simplification would be quite important for finding new 
medicinal leads using complex skeletons of bioactive natural products. DAT can be regarded 
as a master key, at least for tumor promotion and anti-proliferative activity, while 26 can be 
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regarded as a special key for receptors related to anti-proliferative activity. 
The next step is to unveil the molecular mechanism underlying the unique 
biological characteristics of aplogs. Both the anti-proliferative and the tumor-promoting 
activities of PKC ligands have been mostly attributed to its modulating effect on the PKC 
isozymes. However, even pro-apoptotic PKCδ isozymes also mediate survival signaling, and 
other PKC isozymes have dual roles in many cases. Therefore, a careful interpretation of the 
anti-cancer mechanism of PKC ligands is required. Recent studies also found that several C1 
domain-containing proteins such as Ras GRPs and Munc13s are involved in apoptosis 
signaling.[79] Moreover, the existence and involvement of unidentified targets of PKC ligands 
like cytosolic-nuclear tumor promoter-specific binding protein (CN-TPBP)[80] should be 
considered. For this purpose, aplogs could become new molecular probes to identify the 
receptors involved in the anti-proliferative activity other than PKC isozymes. Such studies 
are underway in our laboratory. 
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Figure Captions 
 
Fig. 1. (a) Structure of protein kinase C (PKC) isozymes. Natural PKC ligands like phorbol 
esters as well as 1,2-diacyl-sn-glycerol (DG) bind to the C1 domains of these PKC 
isozymes. (b) Activation of a novel PKC isozyme by natural PKC ligands. Tumor 
promoters or endogenous DG produced by phospholipase C (PLC) bind to the C1A 
and/or C1B domains to induce the plasma membrane translocation. Nuclear 
membrane translocation also occurs depending on the structure and/or 
hydrophobicity of the ligands. C1, protein kinase C conserved region 1; C2, protein 
kinase C conserved region 2; IP3, inositol-1,4,5-triphosphate; PIP2, 
phosphatidylinositol-4,5-diphosphate; PS, phosphatidylserine. 
 
Fig. 2. Structure of 1,2-diacyl-sn-glycerol (DG) receptors with C1 homology domains other 
than PKC isozymes. EF, EF hand; MHD1, 2, Munc13 homology domain 1, 2; PH, 
pleckstrin homology domain; Ras-GEF, guanine nucleotide exchange factor for 
Ras-like small GTPases; REM, Ras exchange motif; Rho-GAP, GTPase-activator 
protein for Rho-like GTPases; SH2, Src homology 2 domain. 
 
Fig. 3. Structure of PKC activators: TPA, ingenol 3-angelate, teleocidin B-4, indolactam-V, 
prostratin, benzolactam-V8s, and DAG-lactones. 
 
Fig. 4. Structure of bryo-1, bryo-7, bryo-10, and simplified analogs of bryo-1 synthesized by 
Wender (1-4) and Keck (5 and 6) 
 
Fig. 5. Structure of ATX, DAT, and their simplified analogs (7-9, 21-27). 
 
Fig. 6. A synthetic route for aplog-1 (7).[55a] 
 
Fig. 7. Correlation between the anti-proliferative activity and log P values. “R” signifies the 
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macrolactone moiety and alkyl side chain of aplog-1 (7). 
 
Fig. 8. Tumor-promoting activity of TPA, 10-methyl-aplog-1 (26), and 
12,12-dimethyl-aplog-1 (27).[71b,72] The back of each male 6-week-old ICR mice was 
shaved with surgical clippers. From a week after initiation by a single application of 
390 nmol of DMBA in 0.1 mL acetone, 8.5 nmol of 26 or 27 in 0.1 mL of acetone 
was applied twice a week from week 1 to week 20. The control group was treated 
with 390 nmol of DMBA and 1.7 nmol of TPA. Anti-tumor-promoting activity of 27 
(8.5 nmol) against TPA (1.7 nmol) is also shown.[72]  Ten male ICR mice were 
tested in each group.  
 
Fig. 9. Values of Ki for the inhibition of [3H]PDBu binding by aplogs (7 and 26) and tumor 
promoters (DAT and indolactam-V).[71b,72] 
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Table 1. Kd and Ki values of the PKC C1 peptides for PDBu and indolactam-V[16d,19] 
 
PKC isozymes PDBu (Kd: nM) Indolactam-V (Ki: nM) 
PKCα (whole) 0.46 20 
PKCα (whole)a 0.15 11 
α-C1A (72-mer) 1.1 21 
α-C1B (72-mer) 5.3 4,000 
PKCβ (whole) 0.54 31 
PKCβ (whole)a 0.14 6.1 
β-C1A (72-mer) 1.3 19 
β-C1B (51-mer) 1.3 140 
PKCγ (whole) 1.8 91 
PKCγ (whole)a 0.37 19 
γ-C1A (52-mer) 1.5 140 
γ-C1B (51-mer) 1.2 210 
PKCδ (whole) 0.76 12 
PKCδ (whole)a 0.71 8.2 
δ-C1A (52-mer) 52 1,900 
δ-C1B (51-mer) 0.53 11 
PKCε (whole) 0.56 6.6 
PKCε (whole)a 0.63 22 
ε-C1A (53-mer) 5.6 4,100 
ε-C1B (51-mer) 0.81 7.7 
PKCη (whole) 0.95 4.8 
PKCη (whole)a 0.58 15.6 
η-C1A (53-mer) 4.3 3,800 
η-C1B (51-mer) 0.45 5.5 
PKCθ (whole) ND ND 
θ-C1A (52-mer) >200 ND 
θ-C1B (51-mer) 0.72 8.7 
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Table 2. Growth inhibition of Wender’s simplified analogs (1 and 2) of bryo-1 against 
several cancer cell lines along with that of bryo-1[46] 
 
   Log GI50 (M)  
Cancer type Cell line 1 2 Bryo-1 
Breast MDA-MB-231 –5.01 –5.69 –5.20 
CNS SF-295 –6.56 –6.05 –5.20 
Colon HCC-2998 –3.50 –7.54 –5.30 
Lung NCI-H460 –7.47 < –8.00 –5.60 
 A549 –6.49 –6.62 –5.20 
Melanoma SK-MEL5 –5.05 –6.43 –5.70 
Ovarian OVACAR-5 > –4.00 –5.28 > –5.00 
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Table 3. Ki values for the inhibition of binding of [3H]PDBu by aplog-1 (7), 8, 9, 
aplysiatoxin (ATX), debromoaplysiatoxin (DAT), and bryo-1 
 
PKCδ and    Ki (nM)   
C1 peptides Aplog-1 (7) 8 9 ATX DAT Bryo-1 
PKCδ 15 400 NTa 3.0 NTa 0.84 
PKCδ-C1A 140 6,800 130 12 9.7 5.3 
PKCδ-C1B 7.4 170 9.8 0.41 0.20 0.60 
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Table 4. Growth inhibition of aplog-1 (7), 8, 9, and debromoaplysiatoxin (DAT) against 
aplog-sensitive cancer cell lines along with that of bryo-1 
 
Cancer type Cell line   Log GI50 (M)   
  Aplog-1 (7) 8 9 DAT Bryo-1 
Breast HBC-4 –6.33 –5.32 –6.20 –6.47 NTa 
 MDA-MB-231 –5.61 –4.55 –5.67 –6.03 –5.20 
CNS SF-295 –5.06 –4.57 –5.14 –4.80 –5.20 
Colon HCC2998 –5.43 –4.57 –5.53 –6.09 –5.30 
Lung NCI-H460 –5.60 –4.70 –5.83 –6.46 –5.60 
 A549 –5.32 –4.48 –5.49 –5.94 –5.20 
Melanoma LOX-IMVI –5.74 –4.66 –5.17 –5.69 NTa 
Stomach St-4 –5.55 –5.04 –6.05 –6.44 NTa 
 MKN45 –5.33 –4.74 –6.09 –4.98 NTa 
MG-MID of 
cell lines 
39 cancer –4.98 –4.27 –5.09 –5.22 — 
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Table 5. Growth inhibition of aplog-1 (7), 27-(R)-methyl-aplog-1 (21), whose absolute 
configuration at position 27 is the same as that of DAT at position 30, the 
27-epimer of 21 (22), and 27-O-methyl-aplog-1 (23) against several cancer cell 
lines 
 
Cancer type Cell line  Log GI50 (M)   
  Aplog-1 (7) 21 22 23 
Breast HBC-4 –6.33 –6.15 –4.78 –4.71 
Lung NCI-H460 –5.60 –5.66 –4.78 –4.70 
Melanoma LOX-IMVI –5.74 –5.18 –4.76 –4.80 
Stomach St-4 –5.55 –5.17 –4.71 –4.70 
Breast MCF-7 –4.72 –4.73 –4.79 –4.88 
Lung DMS114 –4.79 –4.82 –4.82 –4.88 
Stomach MKN74 –4.76 –4.80 –4.76 –4.80 
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Table 6. Growth inhibition of demethoxy-DAT (24), 4-methyl-aplog-1 (25), 
10-methyl-aplog-1 (26), and 12,12-dimethyl-aplog-1 (27) against aplog-sensitive 
cancer cell lines 
 
Cancer type Cell line   Log GI50 (M)  
  24 25 26 27 
Breast HBC-4 < –8.00 –6.56 –7.48 –6.67 
 MDA-MB-231 –7.31 –5.81 –6.90 –5.92 
CNS SF-295 –5.53 –5.14 –4.98 –5.32 
Colon HCC2998 –7.16 –5.39 –6.47 –6.06 
Lung NCI-H460 < –8.00 –5.90 –7.07 –6.05 
 A549 –6.84 –5.13 –6.01 –5.51 
Melanoma LOX-IMVI –5.79 –5.38 –6.21 –6.06 
Stomach St-4 –7.89 –5.22 –6.24 –6.20 
 MKN45 –5.17 –5.90 –4.97 –5.33 
MG-MID of 
cell lines 
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